These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 37451298)

  • 1. Lenacapavir: an attractive option, but proceed with caution.
    Harris M
    Lancet HIV; 2023 Aug; 10(8):e486-e487. PubMed ID: 37451298
    [No Abstract]   [Full Text] [Related]  

  • 2. Lenacapavir (Sunlenca) for multidrug-resistant HIV.
    Med Lett Drugs Ther; 2023 May; 65(1675):68-70. PubMed ID: 37155250
    [No Abstract]   [Full Text] [Related]  

  • 3. Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial.
    Gupta SK; Berhe M; Crofoot G; Benson P; Ramgopal M; Sims J; McDonald C; Ruane P; Sanchez WE; Scribner A; Liu SY; VanderVeen LA; Dvory-Sobol H; Rhee MS; Baeten JM; Koenig E
    Lancet HIV; 2023 Jan; 10(1):e15-e23. PubMed ID: 36566079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial.
    Ogbuagu O; Segal-Maurer S; Ratanasuwan W; Avihingsanon A; Brinson C; Workowski K; Antinori A; Yazdanpanah Y; Trottier B; Wang H; Margot N; Dvory-Sobol H; Rhee MS; Baeten JM; Molina JM;
    Lancet HIV; 2023 Aug; 10(8):e497-e505. PubMed ID: 37451297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lenacapavir.
    Beninger P
    Clin Ther; 2024 Feb; 46(2):183-184. PubMed ID: 38326158
    [No Abstract]   [Full Text] [Related]  

  • 6. Lenacapavir: a twice-yearly treatment for adults with multidrug-resistant HIV infection and limited treatment options.
    Tuan J; Ogbuagu O
    Expert Rev Anti Infect Ther; 2023 Jun; 21(6):565-570. PubMed ID: 37067160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lenacapavir: First Approval.
    Paik J
    Drugs; 2022 Sep; 82(14):1499-1504. PubMed ID: 36272024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection.
    Segal-Maurer S; DeJesus E; Stellbrink HJ; Castagna A; Richmond GJ; Sinclair GI; Siripassorn K; Ruane PJ; Berhe M; Wang H; Margot NA; Dvory-Sobol H; Hyland RH; Brainard DM; Rhee MS; Baeten JM; Molina JM;
    N Engl J Med; 2022 May; 386(19):1793-1803. PubMed ID: 35544387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phenotypic resistance to lenacapavir and monotherapy efficacy in a proof-of-concept clinical study.
    Margot N; Vanderveen L; Naik V; Ram R; Parvangada PC; Martin R; Rhee M; Callebaut C
    J Antimicrob Chemother; 2022 Mar; 77(4):989-995. PubMed ID: 35028668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lenacapavir for HIV-1 - Potential Promise of a Long-Acting Antiretroviral Drug.
    Marrazzo J
    N Engl J Med; 2022 May; 386(19):1848-1849. PubMed ID: 35544391
    [No Abstract]   [Full Text] [Related]  

  • 11. Evaluation of HIV-1 capsid genetic variability and lenacapavir (GS-6207) drug resistance-associated mutations according to viral clades among drug-naive individuals.
    Nka AD; Bouba Y; Teto G; Semengue ENJ; Takou DK; Ngueko AMK; Fabeni L; Carioti L; Armenia D; Pabo W; Dambaya B; Sosso SM; Colizzi V; Perno CF; Ceccherini-Silberstein F; Santoro MM; Fokam J; Ndjolo A
    J Antimicrob Chemother; 2022 Dec; 78(1):272-275. PubMed ID: 36411257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Caution: should we be treating HIV infection early?
    Levy JA
    Lancet; 1998 Sep; 352(9132):982-3. PubMed ID: 9752836
    [No Abstract]   [Full Text] [Related]  

  • 13. Highlights on the Development, Related Patents, and Prospects of Lenacapavir: The First-in-Class HIV-1 Capsid Inhibitor for the Treatment of Multi-Drug-Resistant HIV-1 Infection.
    Dzinamarira T; Almehmadi M; Alsaiari AA; Allahyani M; Aljuaid A; Alsharif A; Khan A; Kamal M; Rabaan AA; Alfaraj AH; AlShehail BM; Alotaibi N; AlShehail SM; Imran M
    Medicina (Kaunas); 2023 May; 59(6):. PubMed ID: 37374245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ADA. Employee allowed to proceed with HIV disability lawsuit.
    AIDS Policy Law; 2009 Dec; 25(1):6. PubMed ID: 20140981
    [No Abstract]   [Full Text] [Related]  

  • 15. HIV-1 capsid inhibitors: a sword to destroy the virus.
    Zhang X; Xu S; Sun L; Ding D; Tao Y; Kang D; Liu X; Zhan P
    Future Med Chem; 2022 May; 14(9):605-607. PubMed ID: 35297282
    [No Abstract]   [Full Text] [Related]  

  • 16. [HIV 1999: suppression at what price?].
    Vernazza PL
    Schweiz Med Wochenschr; 1999 Dec; 129(51-52):2010-3. PubMed ID: 10674310
    [No Abstract]   [Full Text] [Related]  

  • 17. Drug interactions with drugs used in the treatment of HIV and infective complications peculiar to HIV infected patients.
    Griffin JP
    Adverse Drug React Toxicol Rev; 2000 Mar; 19(1):47-88. PubMed ID: 10826280
    [No Abstract]   [Full Text] [Related]  

  • 18. HIV therapy and diabetes risk.
    Dagogo-Jack S
    Diabetes Care; 2008 Jun; 31(6):1267-8. PubMed ID: 18509145
    [No Abstract]   [Full Text] [Related]  

  • 19. Experts hear sobering side of HIV-1 treatment story.
    Morris K
    Lancet; 2000 Feb; 355(9203):555. PubMed ID: 10683014
    [No Abstract]   [Full Text] [Related]  

  • 20. Body image and the complications of HIV treatment.
    Chapman E
    Focus; 2002 Jul; 17(8):1-5. PubMed ID: 14626979
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.